-
Mashup Score: 1Combining post-transplant cyclophosphamide with antithymocyte globulin for graft-versus-host disease prophylaxis in hematological malignancies - 12 month(s) ago
In search of an ideal partner or alternative to conventional immunosuppressive agents, rabbit anti-thymocyte globulin (ATG) and, more recently, post-t…
Source: www.sciencedirect.comCategories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 6
Introduction: Graft-versus host disease (GVHD) is a major limitation to the success of allogeneic hematopoietic cell transplant (HCT). We hypothesized that the GVHD prophylaxis regimen of post-transplant cyclophosphamide (PTCy), tacrolimus (Tac) and mycophenolate mofetil (MMF) would reduce the incidence of GVHD in patients receiving a matched or single antigen mismatched HCT without an increase…
Source: medRxivCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
PTCy plus tacrolimus and MMF should be standard GVHD prophylaxis in adults who receive a well-matched PBSCT after RIC, according to researchers.
Source: Oncology Nurse AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Although post-transplant cyclophosphamide (PT-Cy) is effective for graft-versus-host disease (GVHD) prophylaxis, it is associated with toxicities, which might be dose-dependent. We compared the outcomes with PT-Cy at 80 mg/kg to those with PT-Cy at 100 mg/kg in elderly patients undergoing haploidentical hematopoietic cell transplantation (HCT). Inclusion criteria included peripheral blood stem…
Source: NatureCategories: Hematologists1, Latest HeadlinesTweet-
Happy to share our latest work! Reducing PT-Cy total dose to 80 mg/kg is a safe and valid approach in elderly patients with hematological malignancies undergoing haploidentical PBSC transplantation. ARTICLE 👉 https://t.co/7DljtGQmxk Cc @Mohty_EBMT @Florent_Malard #BMTsm #PTCy https://t.co/uECW7QItl0
-
-
Mashup Score: 1
Allogeneic hematopoietic cell transplantation (HCT) is recommended in high-risk patients with T cell acute lymphoblastic leukemia (T-ALL). For patient…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2
Haploidentical bone marrow transplantation using this approach results in excellent overall survival with minimal GVHD in patients who have not responded to immunosuppressive therapy, and can expand access to bone marrow transplantation across all populations. In clinical practice, this could now be considered a standard approach for salvage treatment of severe aplastic anaemia. Attention to…
Source: The Lancet HaematologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Hematopoietic Cell Transplantation and Cell therapy weekly newsletter 26/05/2022- Issue #9 - 2 year(s) ago
THIS WEEK SUMMARY:Axicel real-world data in B cell LymphomaNeurofilament light chain as ICANS biomarkerMRD status pre alloHCT in CR1 vs CR2CD19/22 bicistronic CART for B ALLand many more…
Source: www.getrevue.coCategories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 4Hematopoietic Cell Transplantation and Cell therapy weekly newsletter 19/05/2022- Issue #8 - 2 year(s) ago
THIS WEEK at a glance:HLA-DQ and its impact in alloHCTPhenotypic composition role of commercial anti-CD19 CARTFluMel vs FluTreo in alloHCTPTCy tacrolimus vs standard GVHD prophylaxis for MSD and MUD donorsAlloHCT for ALL in modern eraand many more!
Source: www.getrevue.coCategories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 1
Request PDF | Successful Haploidentical Stem Cell Transplant With Posttransplant Cyclophosphamide for Isolated Central Nervous System Blast Crisis in a Child With Chronic Myeloid Leukemia | Chronic myelogenous leukemia (CML) is a myeloproliferative disorder. The extramedullary blast crisis (BC) is a known complication of CML, but it… | Find, read and cite all the research you need on…
Source: ResearchGateCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 3
Allogeneic hematopoietic stem cell transplantation (HCT) can cure primary immunodeficiency diseases (PID). When a HLA-matched donor is not available, …
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet
Happy to share our comprehensive review on the combination of PT-Cy and ATG for GVHD prophylaxis in hematological malignancies. Cc @Mohty_EBMT #BloodReviews #GVHD #BMTsm #PTCy https://t.co/3UYdTUbNj6